Literature DB >> 6776144

A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins.

K H Weisgraber, T P Bersot, R W Mahley, G Franceschini, C R Sirtori.   

Abstract

A recently discovered familial lipoprotein disorder is characterized by reduced plasma levels of high density lipoproteins (HDL) and elevated triglyceride levels. The clinical aspects of this disorder are presented in an accompanying article (Franceschini et al. 1980. J. Clin. Invest. 66: 892-900). The apoprotein content of the HDL isolated from these patients differed markedly from that of normal HDL in that three apoprotein bands not previously described in man were present as major protein components. As determined by sodium dodecyl sulfate (SDS) gel electrophoresis, the relative molecular weights (Mr) of these new apoprotein bands were 55,000, 35,000, and 28,000. Although the Mr 28,000 apoprotein coelectrophoresed with authentic A-I on SDS polyacrylamide gels and showed immunochemical identity with the A-I apoprotein when tested with monospecific apo-A-I antiserum, it contained two amino acid residues, cysteine and isoleucine, which were not present in the amino acid sequence of normal human apo-A-I. This variant form of the A-I apoprotein was designated the A-IMilano apoprotein and denoted A-Icys. By virtue of the presence of cysteine (2 mol/mol A-Icys), the A-Icys apoprotein was capable of forming intermolecular disulfide bonds, and dimer formation of A-Icys produced the Mr 55,000 apoprotein. The Mr 35,000 apoprotein was composed of two different subunits, A-Icys and A-II. By analogy to the apo(E--A-II) complex, which also occurs in human HDL, this mixed disulfide complex was designated as the apo(A-Icys--A-II) complex. The A-IMilano (A-Icys) is the first example of a variation in the primary sequence of a protein of plasma lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776144      PMCID: PMC371524          DOI: 10.1172/JCI109957

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  The pathology of Tangier disease. A light and electron microscopic study.

Authors:  V J Ferrans; D S Fredrickson
Journal:  Am J Pathol       Date:  1975-01       Impact factor: 4.307

2.  The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). II. The amino acid sequence and alignment of cyanogen bromide fragments IV, III, and I.

Authors:  H N Baker; A M Gotto; R L Jackson
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

3.  A single amino Acid substitution (asparagine to aspartic Acid) between normal (b+) and the common negro variant (a+) of human glucose-6-phosphate dehydrogenase.

Authors:  A Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1967-03       Impact factor: 11.205

4.  The lipoprotein abnormality in Tangier disease: quantitation of A apoproteins.

Authors:  G Assmann; E Smootz; K Adler; A Capurso; K Oette
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

5.  Properties of the plasma very low and low density lipoproteins in Tangier disease.

Authors:  R J Heinen; P N Herbert; D S Fredrickson
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

6.  Isolation and characterization of two threonine-poor apolipoproteins of human plasma high density lipoproteins.

Authors:  V G Shore; B Shore; S B Lewis
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

7.  Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography.

Authors:  K H Weisgraber; R W Mahley
Journal:  J Lipid Res       Date:  1980-03       Impact factor: 5.922

8.  Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia.

Authors:  L A Carlson; B Philipson
Journal:  Lancet       Date:  1979-11-03       Impact factor: 79.321

9.  Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia.

Authors:  A Pagnan; R J Havel; J P Kane; L Kotite
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

10.  A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family.

Authors:  G Franceschini; C R Sirtori; A Capurso; K H Weisgraber; R W Mahley
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more
  24 in total

1.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

Review 2.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G(*) apolipoprotein J peptide using solution NMR.

Authors:  Vinod K Mishra; Mayakonda N Palgunachari; Jason S Hudson; Ronald Shin; Tamara D Keenum; N Rama Krishna; G M Anantharamaiah
Journal:  Biochim Biophys Acta       Date:  2010-10-21

4.  AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission.

Authors:  V Gualandri; G Franceschini; C R Sirtori; G Gianfranceschi; G B Orsini; A Cerrone; A Menotti
Journal:  Am J Hum Genet       Date:  1985-11       Impact factor: 11.025

5.  Haplotypes identified by DNA restriction-fragment-length polymorphisms in the A-1 C-III A-IV gene region and hypertriglyceridemia.

Authors:  J Stocks; H Paul; D Galton
Journal:  Am J Hum Genet       Date:  1987-08       Impact factor: 11.025

6.  [Apolipoproteinopathies].

Authors:  G Assmann
Journal:  Klin Wochenschr       Date:  1983-02-15

7.  Successful treatment of established heart failure in mice with recombinant HDL (Milano).

Authors:  Joseph Pierre Aboumsallem; Mudit Mishra; Ruhul Amin; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Br J Pharmacol       Date:  2018-09-19       Impact factor: 8.739

8.  Isolation and characterization of cDNA clones for human apolipoprotein A-I.

Authors:  J L Breslow; D Ross; J McPherson; H Williams; D Kurnit; A L Nussbaum; S K Karathanasis; V I Zannis
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

9.  Genetic studies of an apoA-I lipoprotein variant.

Authors:  O Schamaun; B Olaisen; T Gedde-Dahl; P Teisberg
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

10.  Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux.

Authors:  M C Cheung; A J Mendez; A C Wolf; R H Knopp
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.